获取途径

作者

Rong Ding, Jin-Feng Bai, Zhi-Cheng Jin, Yu-Dong Xiao, Jian-Jian Chen, Xiao-Li Zhu, Yu-Jing Xin, Jin-Zhang Chen, Jun Tie, Kang-Shun Zhu, Lan Zhang, Hai-Bin Shi, Rui-Bao Liu, Ai-Bing Xu, Fanpu Ji, Ming-Sheng Huang, Jian-Song Ji, Chun-Wang Yuan, Wei-Zhu Yang, Guo-Hui Xu, Qiang Tu, Hua Jiang, Hai-Bo Shao, Bao-Qi Shi, Ming Huang, Bin-Yan Zhong, Hai-Dong Zhu, Zheng-Gang Ren, Gao-Jun Teng

作者单位

Affiliations ¹ Department of Minimally Invasive Intervention, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China. ² Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China. ³ Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China. ⁴ Department of Radiology, The Second Xiangya Hospital of Central South University, Hunan, China. ⁵ Department of Interventional Radiology, Sichuan Cancer Hospital and Institute, Chengdu, China. ⁶ Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, China. ⁷ Department of Minimally Invasive Comprehensive Treatment of Cancer, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. ⁸ State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. ⁹ National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi'an, China. ¹⁰ Department of Minimally Invasive Interventional Radiology and Radiology Center, and Minimally Invasive and Interventional Cancer Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. ¹¹ Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China. ¹² Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China. ¹³ Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. ¹⁴ Department of Interventional Radiology, The Tumor Hospital of Harbin Medical University, Harbin, China. ¹⁵ Department of Interventional Therapy, Nantong Tumor Hospital, Nantong, China. ¹⁶ Department of Hepatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. ¹⁷ Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry of Education of China, Xi'an, China. ¹⁸ Department of Interventional Radiology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. ¹⁹ Department of Radiology, Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, School of Medicine, Lishui Hospital of Zhejiang University, Lishui, China. ²⁰ Center of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China. ²¹ Department of Interventional Radiology, Union Hospital of Fujian Medical University, Fuzhou, China. ²² Department of Hepatobiliary Oncology Surgery, Department of Interventional Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, China. ²³ Cancer Treatment Centers, Second Affiliated Hospital of Kunming Medical University, Kunming, China. ²⁴ Department of Interventional Radiology, The First Hospital of China Medical University, Shenyang, China. ²⁵ Department of Intervention, Inner Mongolia People's Hospital, Hohhot, China. ²⁶ Department of Interventional Radiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.

刊名

Alimentary pharmacology & therapeutics

年份

2026

ISSN

1365-2036

关键词

apatinib camrelizumab hepatocellular carcinoma prognosis transarterial chemoembolisation.

摘要

Background: This real-world study aimed to evaluate and compare the efficacy and safety of two treatment strategies for advanced hepatocellular carcinoma : transarterial chemoembolisation combined with camrelizumab and apatinib versus camrelizumab and apatinib alone. Methods: In this nationwide, multi-centre retrospective cohort study, data were collected on patients with advanced HCC who received either TACE combined with camrelizumab and apatinib or camrelizumab and apatinib alone between J...更多

Background: This real-world study aimed to evaluate and compare the efficacy and safety of two treatment strategies for advanced hepatocellular carcinoma : transarterial chemoembolisation combined with camrelizumab and apatinib versus camrelizumab and apatinib alone. Methods: In this nationwide, multi-centre retrospective cohort study, data were collected on patients with advanced HCC who received either TACE combined with camrelizumab and apatinib or camrelizumab and apatinib alone between January 2018 and December 2022. To reduce potential bias, stabilised inverse probability of treatment weighting was applied. The primary outcome was overall survival , while secondary outcomes included progression-free survival , objective response rate based on RECIST v1.1 criteria, and safety. Results: A total of 252 HCC patients were included . Among them, 210 were males and 42 were females, with a median age of 54 years. After sIPTW, the median OS was significantly longer in the T-C-A group compared to the C-A group . The T-C-A group also demonstrated a significantly improved median PFS of 10.1 months [95% CI: 8.8-12.2], compared to 4.9 months [95% CI: 4.0-12.5] in the C-A group . Further, the ORR was higher in the T-C-A group. Grade 3/4 adverse events were reported in 12.0% of patients in the T-C-A group and 14.5% in the C-A group. Conclusion: The combination of TACE with camrelizumab and apatinib suggests potential survival advantages for patients with advanced HCC while maintaining an acceptable safety profile.收起

文献类型

期刊

浏览量

4